COVID-19疫苗在老年人群中的有效性至关重要
该研究以加拿大不列颠哥伦比亚省全人群为对象,用年龄分层的区室数学模型评估不同COVID-19疫苗策略的效果。结果显示,要降低全人群感染率需在各年龄组高覆盖率接种,而要大幅降低65岁及以上人群死亡率,疫苗必须直接保护该人群中的高比例个体。作者建议未来候选疫苗试验纳入65岁及以上人群,并在接种后监测老年组的疫苗有效性。
要点
- 降低全人群感染率需所有年龄组高接种率。
- 大幅降低65岁及以上人群死亡率需疫苗直接保护该人群。
- 建议未来疫苗试验纳入65岁及以上人群并监测其有效性。
核心结论
- 有效疫苗大规模接种可显著减少易感人群感染,但除非疫苗对老年人也有直接保护作用,否则总体死亡率不会大幅下降。
研究设计与样本
- 采用区室数学模型,按年龄和接触水平构建人群结构,校准模拟加拿大不列颠哥伦比亚省全人群的疫情进程,并假设在成人中显示高效力的疫苗会被部署,同时考察老年人群疫苗效力较低的情形。
主要发现
- 要降低全人群总体感染率,向所有年龄组高接种率部署至关重要。
- 要大幅降低65岁及以上人群死亡率,疫苗必须直接保护该人群中的高比例个体。
- 即使通过儿童和年轻成人接种高效阻断传播,若疫苗对老年人无直接保护,总体死亡率也不会大幅降低。
临床怎么用
- 未来COVID-19候选疫苗试验应纳入65岁及以上人群。
- 接种后应仔细监测老年组的疫苗有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: An effective vaccine against SARS-CoV-2 will reduce morbidity and mortality and allow substantial relaxation of physical distancing policies. However, the ability of a vaccine to prevent infection or disease depends critically on protecting older individuals, who are at highest risk of severe disease. OBJECTIVE: We quantitatively estimated the relative benefits of COVID-19 vaccines, in terms of preventing infection and death, with a particular focus on effectiveness in elderly people. DESIGN: We applied compartmental mathematical modelling to determine the relative effects of vaccines that block infection and onward transmission, and those that prevent severe disease. We assumed that vaccines showing high efficacy in adults would be deployed, and examined the effects of lower vaccine efficacy among the elderly population. SETTING AND PARTICIPANTS: Our mathematical model was calibrated to simulate the course of an epidemic among the entire population of British Columbia, Canada. Within our model, the population was structured by age and levels of contact. MAIN OUTCOME(S) AND MEASURE(S): We assessed the effectiveness of possible vaccines in terms of the predicted number of infections within the entire population, and deaths among people aged 65 years and over. RESULTS: In order to reduce the overall rate of infections in the population, high rates of deployment to all age groups will be critical. However, to substantially reduce mortality among people aged 65 years and over, a vaccine must directly protect a high proportion of people in that group. CONCLUSIONS AND RELEVANCE: Effective vaccines deployed to a large fraction of the population are projected to substantially reduce infection in an otherwise susceptible population. However, even if transmission were blocked highly effectively by vaccination of children and younger adults, overall mortality would not be substantially reduced unless the vaccine is also directly protective in elderly people. We strongly recommend: (i) the inclusion of people aged 65 years and over in future trials of COVID-19 vaccine candidates; (ii) careful monitoring of vaccine efficacy in older age groups following vaccination.
引用
- Sadarangani M, Abu Raya B, Conway JM, et al. Importance of COVID-19 vaccine efficacy in older age groups. Vaccine. 2021. PMID: 33736921. doi:10.1016/j.vaccine.2021.03.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。